search
Back to results

Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 2
Locations
Germany
Study Type
Interventional
Intervention
Placebo
Placebo
Placebo
BI 187004
Placebo
BI 187004
BI 187004
BI 187004
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  1. Male or postmenopausal or hysterectomised female patients with diagnosis of Type 2 Diabetes Mellitus (T2DM) before informed consent
  2. To be eligible for Arm 1

    1. Oral antidiabetic mono-therapy for the last 12 weeks prior to Informed Consent AND Glycosylated haemoglobin (HbA1c) >= 6.5% and <= 8.5% at Visit 1a
    2. Therapy-naïve patients or no antidiabetic treatment within 4 weeks prior to Informed Consent AND HbA1c >= 7.0% and <= 9.5% at Visit 1a.
  3. To be eligible for Arm 2:

    a. Antidiabetic treatment with metformin with an unchanged daily dose for 12 weeks prior to Informed Consent AND patient´s willingness to keep this therapy stable during the course of the trial AND HbA1c >= 7.0% and <= 9.5% at Visit 1a

  4. Age >=18 and <=80 years for female hysterectomised and male patients at Visit 1a
  5. Age >=55 and <=80 years for female postmenopausal (defined by the absence of menses for at least 2 years) patients at Visit 1a
  6. Body mass index (BMI) >= 28 and <= 40 kg/m2 at Visit 1a
  7. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation

Exclusion criteria:

  1. Treatment with a non-oral antidiabetic therapy or with more than one oral antidiabetic medication within 12 weeks prior to visit 1a.
  2. Fasted plasma glucose > 240 mg/dl (>13.3 mmol/l) on two consecutive days after screening (Visit 1a) confirmed by a fasted laboratory blood glucose test until first administration of the trial drug
  3. Any laboratory value more than 3 times above upper limit normal (ULN) at screening (visit 1a) or any other laboratory value outside the reference range and clinically relevant in the investigator judgment
  4. Any known clinically relevant concomitant diseases or chronic diseases other than type 2 diabetes, hyperlipidaemia or medically treated hypertension
  5. Medical history of cancer or treatment for cancer in the last five years prior to the Visit 1a.
  6. History of Cushing syndrome, Addison´s disease, congenital adrenal hyperplasia or polycystic ovary syndrome
  7. Treatment with systemic, inhalatory or ophthalmologic steroids within 12 weeks prior to first administration of the trial drug.
  8. Treatment compliance during the run-in period is outside the per protocol range defined range, between 80%-120% treatment compliance.
  9. Use of any other concomitant medication within 5 half-lives before the first administration of the trial drug except for allowed co-medication.
  10. Surgery or trauma with significant blood loss (more than 500 ml) within the last 3 months prior to informed consent or blood donation (more than 100 ml) within four weeks prior to first administration of study medication or planned during the trial
  11. Any other medical condition that would interfere with trial participation based on investigator´s judgement or any on-going clinical condition that would jeopardize patient´s or site personnel´s safety or study compliance based on investigator judgement. Smoking habits interfering with hospitalization. Patients not willing to abstain from alcoholic beverages during inpatient visits
  12. Male patients not willing to use adequate contraception (sexual abstinence, condom use plus another form of contraception e.g. spermicide, oral contraceptive taken by female partner, sterilisation, intrauterine device) during the whole study period from the time of the first intake of study drug until three months after the last intake

Sites / Locations

  • 1307.4.49003 Boehringer Ingelheim Investigational Site
  • 1307.4.49002 Boehringer Ingelheim Investigational Site
  • 1307.4.49001 Boehringer Ingelheim Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

BI 187004 low dose mono QD

BI 187004 medium dose mono QD

BI 187004 high dose mono QD

BI 187004 high dose QD add on

Arm Description

patient to receive one tablet containing low dose of BI 187004 or matching placebo

patient to receive one tablet containing medium dose mg of BI 187004 or matching placebo

patient to receive one tablet containing high dose of BI 187004 or matching placebo

patient to receive one tablet containing high dose of BI 187004 or matching placebo add on to metformin background dose

Outcomes

Primary Outcome Measures

The percentage of patients with drug- related adverse events

Secondary Outcome Measures

Change from baseline in fasting plasma glucose (FPG) after 28 days of treatment

Full Information

First Posted
May 28, 2014
Last Updated
August 12, 2015
Sponsor
Boehringer Ingelheim
search

1. Study Identification

Unique Protocol Identification Number
NCT02150824
Brief Title
Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin
Official Title
A Randomized, Double-blind, Placebo-controlled, Parallel Groups Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of Three BI 187004 Doses Given Once Daily as Mono-therapy and of the Highest BI 187004 Dose Given Once Daily as Add on Treatment to Metformin Over 28 Days in Patients With Type 2 Diabetes Mellitus
Study Type
Interventional

2. Study Status

Record Verification Date
August 2015
Overall Recruitment Status
Completed
Study Start Date
July 2014 (undefined)
Primary Completion Date
July 2015 (Actual)
Study Completion Date
August 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim

4. Oversight

5. Study Description

Brief Summary
Assess the safety and tolerability of once daily oral doses of BI 187004 in patients with type 2 diabetes mellitus without oral antidiabetic treatment and in patients on a stable metformin background treatment over 28 days. Assess the effect on fasting plasma glucose after 28 days of treatment and to investigate the pharmacokinetics and pharmacodynamics of BI 187004.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
103 (Actual)

8. Arms, Groups, and Interventions

Arm Title
BI 187004 low dose mono QD
Arm Type
Experimental
Arm Description
patient to receive one tablet containing low dose of BI 187004 or matching placebo
Arm Title
BI 187004 medium dose mono QD
Arm Type
Experimental
Arm Description
patient to receive one tablet containing medium dose mg of BI 187004 or matching placebo
Arm Title
BI 187004 high dose mono QD
Arm Type
Experimental
Arm Description
patient to receive one tablet containing high dose of BI 187004 or matching placebo
Arm Title
BI 187004 high dose QD add on
Arm Type
Experimental
Arm Description
patient to receive one tablet containing high dose of BI 187004 or matching placebo add on to metformin background dose
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
BI 187004 high dose matching placebo once daily
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
BI 187004 medium dose matching placebo once daily
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
BI 187004 high dose matching placebo once daily add on to background metformin
Intervention Type
Drug
Intervention Name(s)
BI 187004
Intervention Description
BI 187004 high dose once daily add on to background metformin
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
BI 187004 low dose matching placebo once daily
Intervention Type
Drug
Intervention Name(s)
BI 187004
Intervention Description
BI 187004 medium dose once daily
Intervention Type
Drug
Intervention Name(s)
BI 187004
Intervention Description
BI 187004 low dose once daily
Intervention Type
Drug
Intervention Name(s)
BI 187004
Intervention Description
BI 187004 high dose once daily
Primary Outcome Measure Information:
Title
The percentage of patients with drug- related adverse events
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
Change from baseline in fasting plasma glucose (FPG) after 28 days of treatment
Time Frame
4 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Male or postmenopausal or hysterectomised female patients with diagnosis of Type 2 Diabetes Mellitus (T2DM) before informed consent To be eligible for Arm 1 Oral antidiabetic mono-therapy for the last 12 weeks prior to Informed Consent AND Glycosylated haemoglobin (HbA1c) >= 6.5% and <= 8.5% at Visit 1a Therapy-naïve patients or no antidiabetic treatment within 4 weeks prior to Informed Consent AND HbA1c >= 7.0% and <= 9.5% at Visit 1a. To be eligible for Arm 2: a. Antidiabetic treatment with metformin with an unchanged daily dose for 12 weeks prior to Informed Consent AND patient´s willingness to keep this therapy stable during the course of the trial AND HbA1c >= 7.0% and <= 9.5% at Visit 1a Age >=18 and <=80 years for female hysterectomised and male patients at Visit 1a Age >=55 and <=80 years for female postmenopausal (defined by the absence of menses for at least 2 years) patients at Visit 1a Body mass index (BMI) >= 28 and <= 40 kg/m2 at Visit 1a Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation Exclusion criteria: Treatment with a non-oral antidiabetic therapy or with more than one oral antidiabetic medication within 12 weeks prior to visit 1a. Fasted plasma glucose > 240 mg/dl (>13.3 mmol/l) on two consecutive days after screening (Visit 1a) confirmed by a fasted laboratory blood glucose test until first administration of the trial drug Any laboratory value more than 3 times above upper limit normal (ULN) at screening (visit 1a) or any other laboratory value outside the reference range and clinically relevant in the investigator judgment Any known clinically relevant concomitant diseases or chronic diseases other than type 2 diabetes, hyperlipidaemia or medically treated hypertension Medical history of cancer or treatment for cancer in the last five years prior to the Visit 1a. History of Cushing syndrome, Addison´s disease, congenital adrenal hyperplasia or polycystic ovary syndrome Treatment with systemic, inhalatory or ophthalmologic steroids within 12 weeks prior to first administration of the trial drug. Treatment compliance during the run-in period is outside the per protocol range defined range, between 80%-120% treatment compliance. Use of any other concomitant medication within 5 half-lives before the first administration of the trial drug except for allowed co-medication. Surgery or trauma with significant blood loss (more than 500 ml) within the last 3 months prior to informed consent or blood donation (more than 100 ml) within four weeks prior to first administration of study medication or planned during the trial Any other medical condition that would interfere with trial participation based on investigator´s judgement or any on-going clinical condition that would jeopardize patient´s or site personnel´s safety or study compliance based on investigator judgement. Smoking habits interfering with hospitalization. Patients not willing to abstain from alcoholic beverages during inpatient visits Male patients not willing to use adequate contraception (sexual abstinence, condom use plus another form of contraception e.g. spermicide, oral contraceptive taken by female partner, sterilisation, intrauterine device) during the whole study period from the time of the first intake of study drug until three months after the last intake
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
1307.4.49003 Boehringer Ingelheim Investigational Site
City
Berlin
Country
Germany
Facility Name
1307.4.49002 Boehringer Ingelheim Investigational Site
City
Mainz
Country
Germany
Facility Name
1307.4.49001 Boehringer Ingelheim Investigational Site
City
Neuss
Country
Germany

12. IPD Sharing Statement

Learn more about this trial

Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin

We'll reach out to this number within 24 hrs